BioCatalyst

Ritlecitinib 50 mg, Ritlecitinib 100 mg — catalyst calendar

1 verified catalyst event(s) referencing Ritlecitinib 50 mg, Ritlecitinib 100 mg, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-25
in 3mo
ESTIMATED
 READOUT
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spont
Phase 2 · Chronic Spontaneous Urticaria
 PFE PFIZER INC Ritlecitinib 50 mg, Ritlecitinib 100 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.